CAR T-Cell Therapy in Multiple Myeloma : Episode 3
CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
Panelists discuss the rationale for considering chimeric antigen receptor (CAR) T-cell therapy in standard-risk multiple myeloma and how health care providers help patients understand and prepare for the decision to pursue CAR T-cell treatment.
EP: 1.Navigating the Myeloma Journey: Insights from Diagnosis to First-Line Treatment in Standard-Risk Patient
EP: 2.Exploring CAR-T Therapy: Discussing Its Introduction and Shared Decision-Making in Myeloma Treatment
Now Viewing
EP: 3.CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
EP: 4.CAR-T Therapy Journey: From Cell Collection to Managing Challenges
EP: 5.Preparing for CAR-T Therapy: Key Considerations and Timing in Multiple Myeloma Treatment
EP: 6.Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
EP: 7.Navigating Recovery: CAR-T Cell Therapy Experience
EP: 8.Navigating the Long-Term Landscape: CAR-T Therapy Patient Monitoring and Care
EP: 9.Navigating My Myeloma Journey: Insights and Advice on CAR-T Therapy
EP: 10.The Future of CAR-T: Advancing Myeloma Treatment Strategies
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
- What is the rationale for considering chimeric antigen receptor (CAR) T-cell therapy as a treatment in standard-risk multiple myeloma?
Dr Castaneda: Ask Jammie:
- How do you help patients understand the option of CAR T cell as a therapy, and what is your role in preparing them for this decision?
Recent Videos
Related Content
